ST266 Eyedrops for the Treatment of Persistent Corneal Epithelial Defects
A Phase 2b, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of ST266 Eye Drops in the Treatment of Persistent Corneal Epithelial Defects
Sponsor: IQVIA Biotech
Terminated
Sponsor undergoing financial hardships - no longer able to support trial; no safety concerns.
A PHASE2 clinical study on Persistent Corneal Epithelial Defect, this trial is terminated or withdrawn. The trial is conducted by IQVIA Biotech and has accumulated 11 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Nov 2022 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- IQVIA Biotech
- Noveome Biotherapeutics, formerly Stemnion
For direct contact, visit the study record on ClinicalTrials.gov .